SeaCrest Wealth Management LLC purchased a new stake in Nektar Therapeutics (NASDAQ:NKTR) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 3,350 shares of the biopharmaceutical company’s stock, valued at approximately $200,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Oppenheimer Asset Management Inc. acquired a new stake in Nektar Therapeutics in the 3rd quarter valued at $129,000. Mark Sheptoff Financial Planning LLC increased its holdings in Nektar Therapeutics by 79.4% in the 3rd quarter. Mark Sheptoff Financial Planning LLC now owns 6,100 shares of the biopharmaceutical company’s stock valued at $146,000 after purchasing an additional 2,700 shares in the last quarter. Flinton Capital Management LLC increased its holdings in Nektar Therapeutics by 75.7% in the 2nd quarter. Flinton Capital Management LLC now owns 7,872 shares of the biopharmaceutical company’s stock valued at $154,000 after purchasing an additional 3,392 shares in the last quarter. Kovack Advisors Inc. acquired a new stake in shares of Nektar Therapeutics during the fourth quarter valued at about $240,000. Finally, Sicart Associates LLC acquired a new stake in shares of Nektar Therapeutics during the fourth quarter valued at about $245,000. Hedge funds and other institutional investors own 96.00% of the company’s stock.

Nektar Therapeutics (NASDAQ NKTR) opened at $78.70 on Tuesday. The company has a debt-to-equity ratio of 2.91, a quick ratio of 3.99 and a current ratio of 4.14. Nektar Therapeutics has a 12-month low of $12.50 and a 12-month high of $99.02.

In other news, Director Christopher A. Kuebler sold 30,000 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $58.66, for a total transaction of $1,759,800.00. Following the transaction, the director now owns 70,500 shares of the company’s stock, valued at $4,135,530. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Howard W. Robin sold 83,333 shares of the stock in a transaction dated Wednesday, December 13th. The stock was sold at an average price of $55.69, for a total transaction of $4,640,814.77. Following the transaction, the chief executive officer now directly owns 272,768 shares in the company, valued at approximately $15,190,449.92. The disclosure for this sale can be found here. Insiders have sold 196,666 shares of company stock worth $12,718,923 in the last ninety days. Corporate insiders own 5.44% of the company’s stock.

Several brokerages have recently weighed in on NKTR. BidaskClub downgraded Nektar Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 8th. Zacks Investment Research upgraded Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 16th. Jefferies Group raised their target price on Nektar Therapeutics from $2.12 to $88.00 and gave the company a “buy” rating in a research note on Tuesday, January 16th. Mizuho raised their target price on Nektar Therapeutics from $45.00 to $89.00 and gave the company a “buy” rating in a research note on Monday, January 22nd. Finally, Canaccord Genuity restated a “buy” rating and set a $80.00 target price (up from $50.00) on shares of Nektar Therapeutics in a research note on Wednesday, January 10th. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $46.17.

TRADEMARK VIOLATION WARNING: This report was originally published by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://www.watchlistnews.com/seacrest-wealth-management-llc-purchases-new-holdings-in-nektar-therapeutics-nktr/1862967.html.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTR).

Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.